sk&f 99085 has been researched along with mevalonic acid in 2 studies
| Studies (sk&f 99085) | Trials (sk&f 99085) | Recent Studies (post-2010) (sk&f 99085) | Studies (mevalonic acid) | Trials (mevalonic acid) | Recent Studies (post-2010) (mevalonic acid) |
|---|---|---|---|---|---|
| 15 | 2 | 3 | 3,810 | 33 | 922 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antoni, I; Bentzen, CL; Flach, J; Niesor, EJ; Villemin, P | 1 |
| Ebetino, FH; Edwards, CM; Hulley, PA; Roelofs, AJ; Rogers, MJ; Russell, RG | 1 |
2 other study(ies) available for sk&f 99085 and mevalonic acid
| Article | Year |
|---|---|
The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Cell Division; Diphosphonates; Dose-Response Relationship, Drug; Farnesol; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Molecular Mimicry; Simvastatin; Terpenes; Tumor Cells, Cultured | 2000 |
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Diphosphonates; Down-Regulation; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Multiple Myeloma; Phosphatidylcholines; Protein Prenylation | 2007 |